Inclusion of MUC1 (Ma695) in a panel of immunohistochemical markers is useful for distinguishing between endocervical and endometrial mucinous adenocarcinoma
2006

Using MUC1 to Differentiate Between Two Types of Cancer

Sample size: 32 publication Evidence: high

Author Information

Author(s): Khoury Thaer, Tan Dongfeng, Wang Jianmin, Intengan Marilyn, Yang Jun, Alrawi Sadir, Yan Peisha, Byrd James C

Primary Institution: Roswell Park Cancer Institute, State University of New York at Buffalo

Hypothesis

Can a panel of immunohistochemical markers effectively distinguish between primary endocervical adenocarcinoma and primary endometrial mucinous adenocarcinoma?

Conclusion

A panel of immunohistochemical markers including MUC1, p16, ER, PR, and vimentin is recommended for distinguishing between endocervical and endometrial adenocarcinomas.

Supporting Evidence

  • MUC1 was positive in 78% of endometrial mucinous adenocarcinomas but only 14% of endocervical adenocarcinomas.
  • Estrogen receptor positivity was found in 94% of endometrial mucinous adenocarcinomas compared to 21% in endocervical adenocarcinomas.
  • Progesterone receptor positivity was 89% in endometrial mucinous adenocarcinomas versus 21% in endocervical adenocarcinomas.
  • Vimentin was positive in 50% of endometrial mucinous adenocarcinomas but only 7% in endocervical adenocarcinomas.
  • p16 was positive in 71% of endocervical adenocarcinomas but only 22% of endometrial mucinous adenocarcinomas.

Takeaway

Doctors can use special tests to tell the difference between two types of cancer that start in the female reproductive system, which helps them decide how to treat patients.

Methodology

Immunohistochemistry was performed on 32 cases, including 18 endometrial mucinous adenocarcinomas and 14 endocervical adenocarcinomas, using monoclonal antibodies to various markers.

Limitations

The study was limited by the small sample size and the focus on mucinous subtype only.

Participant Demographics

The study included 32 cases of known origin, with 18 endometrial and 14 endocervical adenocarcinomas.

Statistical Information

P-Value

p < 0.001

Statistical Significance

p < 0.001

Digital Object Identifier (DOI)

10.1186/1472-6890-6-1

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication